Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2021.11.002 http://scihub22266oqcxt.onion/10.1016/j.drudis.2021.11.002 34763066!8574122!34763066     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Today 2022 ; 27 (3): 848-856 Nephropedia Template TP {{tp|p=34763066|t=2022. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19 |pdf=|usr=}}{{34763066}} gab.com Text The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19 JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=34763066 #FOAvip Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global health. The disregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) cell signaling pathway observed in patients with COVID-19 has attracted attention for the possible use of specific inhibitors of this pathway for the treatment of the disease. Here, we review emerging data on the involvement of the PI3K/Akt/mTOR pathway in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the clinical studies investigating its tailored inhibition in COVID-19. Current in silico, in vitro, and in vivo data convergently support a role for the PI3K/Akt/mTOR pathway in COVID-19 and suggest the use of specific inhibitors of this pathway that, by a combined mechanism entailing downregulation of excessive inflammatory reactions, cell protection, and antiviral effects, could ameliorate the course of COVID-19. Twit Text FOAVip The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19 ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=34763066 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34763066 #FOAvip English Wikipedia <ref>{{Cite pmid|34763066}}</ref> The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19 #MMPMID34763066 Basile MS; Cavalli E; McCubrey J; Hernandez-Bello J; Munoz-Valle JF; Fagone P; Nicoletti F Drug Discov Today 2022[Mar]; 27 (3): 848-856 PMID34763066show ga Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global health. The disregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) cell signaling pathway observed in patients with COVID-19 has attracted attention for the possible use of specific inhibitors of this pathway for the treatment of the disease. Here, we review emerging data on the involvement of the PI3K/Akt/mTOR pathway in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the clinical studies investigating its tailored inhibition in COVID-19. Current in silico, in vitro, and in vivo data convergently support a role for the PI3K/Akt/mTOR pathway in COVID-19 and suggest the use of specific inhibitors of this pathway that, by a combined mechanism entailing downregulation of excessive inflammatory reactions, cell protection, and antiviral effects, could ameliorate the course of COVID-19. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |COVID-19/metabolism[MESH] |Humans[MESH] |Phosphatidylinositol 3-Kinases/*metabolism[MESH] |Protein Kinase Inhibitors/*pharmacology[MESH] |Proto-Oncogene Proteins c-akt/*metabolism[MESH] |Signal Transduction/*drug effects[MESH]The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID(epmc).pdf DeepDyve Pubget Overpricing